Metastatic Breast Cancer

FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer

The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Etcamah (camizestrant), used with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib), for breast cancer.

Prestige BioPharma and Dr. Reddy’s partner to sell trastuzumab biosimilar

Prestige BioPharma and Dr. Reddy’s Laboratories have signed a binding agreement to commercialise the former’s trastuzumab (HD201) biosimilar in select Latin America and Southeast Asian countries.

Gilead’s Trodelvy secures EC approval for Metastatic TNBC treatment

Gilead Sciences has received marketing authorisation from the European Commission (EC) for Trodelvy (sacituzumab govitecan) to treat adult patients suffering from unresectable or metastatic triple-negative breast cancer (TNBC).